Covid-19: Deployment of treatments for highest risk non-hospitalised patients

  • Home
  • News
  • Covid-19: Deployment of treatments for highest risk non-hospitalised patients
NCL Wide
Add to CPD

NCL nMAb briefing update GP  (updated 24.12.21 policy) can be found below in downloads

University College London Hospitals (UCLH) will be administering new Covid-19 treatments for patients at highest risk in the community from Thursday 16 December. This will begin with prescribing oral antivirals and progress to IV antibody treatments from Monday 20 December.

Neutralising monoclonal antibodies (nMABs) or antiviral treatments for the highest risk non-hospitalised patients with Covid-19 are being given to patients at a dedicated clinic on the ground floor of University College Hospital. This will be known as the nMAB CMDU (Covid Medical Delivery Unit).

nMABs are an intravenous treatment and are recommended to be available as a treatment option for non-hospitalised adults and children (aged 12 years and above) in the nationally identified highest risk patient cohorts. The Updated CAS alert has now been published and eligibility is described in Appendix 1. 

More information about the treatments can be found on the MHRA website.  

In addition to the intravenous treatment, the CMDU at UCLH will also offer an oral antiviral as an alternative for patients for whom the intravenous treatment is not feasible/contraindicated. Patients will not need to attend the CMDU for this treatment.

Most of the highest risk patients will receive a letter or email telling them in advance they may be eligible for these treatments in the event they test PCR positive for Covid-19. They will also automatically receive a priority PCR test to keep at home. It is anticipated that 15 per cent of patients will be referred from either 111 services, by their GP or their specialist who identify patients that are not captured as part of the national database. These referrals will be made via Directory of Services or eRS and clinical triage will then be undertaken by the CMDU.

The CMDU will be operating sufficient hours to enable treatments to be given within the set time frames, with the ambition to deliver a seven day service if required. Patient transport will be provided for those who cannot arrange travel but need to attend the CMDU service for their intravenous infusion. A pharmacy delivery service will also be made available for those who cannot arrange for the collection of their oral antiviral treatments.  

In the event of a positive PCR test eligible high risk patients will be contacted directly to discuss the treatment and confirm eligibility.

Whittington Health Community services will also be working alongside the CMDU to arrange any ongoing support some patients may need following treatment.

For your information, the patient SMS text message and letter has been attached along with the Easy Read patient information leaflet.

For more information about the service, email or call 07526 971 953. 

CAS alert: Neutralising monoclonal antibodies (nMABs) or antivirals for non-hospitalised patients with Covid-19


Interim Clinical Commissioning Policy: Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19


Covid Medicines Delivery Unit (CMDU)


Patient notification letter: Important information about new treatments for coronavirus

Download PDF, 137.09 KB

Easy read patient notification letter

Download PDF, 1.29 MB

Patient email and SMS following positive test

Download PDF, 208.95 KB


Expiry date: Feb 15th, 2099